Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 20 EU countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: Assessing medical devices: a qualitative study from the validate perspective

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Bloemen et al. analyzed the procedures and methods used by health technology assessment (HTA) agencies in evaluating medical devices, focusing on the normative commitments of HTA practitioners. The authors revealed that existing drug-focused frameworks and practical constraints limit innovation, underscoring the need for a re-evaluation of HTA roles and institutional changes to support methodological advancements tailored for medical devices.

Access the full-text article here.